

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma

Information for the public Published: 28 April 2021

www.nice.org.uk

Carfilzomib (Kyprolis) plus lenalidomide and dexamethasone is available on the NHS as a treatment option for multiple myeloma in adults. This is only if you have had 1 previous treatment that included bortezomib.

If you are not eligible for carfilzomib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about <u>making decisions about your care</u>.

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The <u>NHS website</u> may be a good place to find out more about <u>myeloma</u>.

These organisations can give you advice and support:

- <u>Myeloma UK</u>, 0800 980 3332
- UK Myeloma Forum
- <u>Blood Cancer UK</u>, 0808 169 5155
- <u>Cancer Research UK</u>, 0808 800 4040
- Macmillan Cancer Support, 0808 808 00 00

You can also get support from your local <u>Healthwatch</u>.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4102-5